Risk factor
Limited trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Everlight Chemical Industrial Corporation, founded in Taipei, Taiwan, in 1972, operates as a global producer and distributor of a diverse array of chemical products. Its extensive market reach spans Taiwan, the broader Asian region, the United States, Europe, and other international territories. The company's product portfolio encompasses a comprehensive range of dyes, including those for textiles, leather, inkjet printing, metals, paper, and advanced functional chemicals for fabric applications, digital textile solutions, and solar-sensitized dyes. Furthermore, Everlight provides specialized chemical additives such as light stabilizers, crucial for enhancing the durability of weather-resistant coatings and plastics, alongside anti-yellowing agents for polyurethane and thermoplastic polyurethane materials, and essential raw materials for sunscreen cosmetic formulations. In the pharmaceutical sector, it develops and manufactures active pharmaceutical ingredients (APIs), notably prostaglandin APIs, as well as APIs for treating cardiovascular conditions and Parkinson's disease. For the electronics industry, the corporation supplies high-performance materials like photoresists, developers, polishing solutions, and sophisticated functional surface nano-coatings designed for integrated circuits (ICs), liquid crystal displays (LCDs), light-emitting diodes (LEDs), and touch panel (TP) applications. Additionally, it produces and markets imaging consumables, including toner and cartridges, compatible with laser printers, photocopiers, and fax machines. Beyond manufacturing, the company actively engages in the trading of chemical products and raw materials, offers expert technical consulting services, and produces pigments, toners, and specialized chemicals for electronic applications.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI